Full-Time
Confirmed live in the last 24 hours
Non-invasive cardiac testing for heart disease
$240k - $280k/yr
Senior
Washington, USA + 2 more
More locations: Oregon, USA | California, USA
Candidates must be based in California, Washington, or Oregon.
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to create more effective treatment plans for heart disease, making cardiovascular care safer and more efficient. Unlike traditional methods that may require invasive procedures, HeartFlow's approach reduces risks for patients and lowers costs for healthcare providers. The company's main product, the HeartFlow Analysis, includes various analyses such as FFRCT Analysis and Plaque Analysis, and has received FDA clearance for use in the United States, as well as approvals in the UK, Japan, and Canada. HeartFlow differentiates itself from competitors by focusing on non-invasive diagnostics and offering a comprehensive suite of tools for heart disease management. The company's goal is to improve the diagnosis and treatment of heart disease, ultimately enhancing patient care.
Company Size
501-1,000
Company Stage
Debt Financing
Total Funding
$1B
Headquarters
Redwood City, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Stock Options
401(k) Company Match
HeartFlow has filed a notice for an exempt offering of securities to raise $50 million in new debt financing. This filing with the U.S. Securities and Exchange Commission is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, specifically under Rule 504 or 506 of Regulation D or Section 4(a)(5). The notice must be filed within 15 days after the first sale of securities in the offering.
Heartflow, Inc. announced a $98 million convertible notes financing led by its parent company, Heartflow Holding, Inc. New and existing investors, including Fidelity Management, Janus Henderson, and Bain Capital, participated. The funds will support R&D to advance Heartflow's AI-driven coronary care platform. Heartflow's technology, recognized for innovation, aims to improve CAD diagnosis and management. The platform has been used for over 400,000 patients globally.
Heartflow was recently named one of Fast Company's Most Innovative Companies in Medical Devices for 2025 and won the Innovation in Cardiac Imaging award at the Global Cardiovascular Awards 2025.
HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers
HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.